Michele De Palma

List of Publications by Year in Descending Order

78 papers	11,426 citations	47 h-index	87 g-index
87 ext. papers	13,359 ext. citations	16.5 avg, IF	6.61 L-index

#	Paper	IF	Citations
78	Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth **2022**, 1, 476-490		0
77	Alzheimer's drug turns macrophages against cancer.. *Nature Cancer*, **2021**, 2, 1119-1121	15.4	1
76	Disentangling the complexity of tumor-derived extracellular vesicles. *Cell Reports*, **2021**, 35, 108960	10.6	4
75	Imaging-based spectrometer-less optofluidic biosensors based on dielectric metasurfaces for detecting extracellular vesicles. *Nature Communications*, **2021**, 12, 3246	17.4	36
74	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. *Science Translational Medicine*, **2021**, 13,	17.5	5
73	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. *Science Translational Medicine*, **2021**, 13,	17.5	9
72	Biology and therapeutic targeting of tumour-associated macrophages. *Journal of Pathology*, **2020**, 250, 573-592	9.4	41
71	A LIGHTning Strike to the Metastatic Niche. *Cell Reports*, **2020**, 30, 599-601	10.6	2
70	Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. *Journal of Clinical Investigation*, **2020**, 130, 1199-1216	15.9	19
69	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 541-551	11.5	34
68	Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. *Cell Reports*, **2019**, 27, 3062-3080.e11	10.6	62
67	Macrophage interference on chemotherapy. *Nature Cell Biology*, **2019**, 21, 411-412	23.4	5
66	Sequential Bone-Marrow Cell Delivery of VEGFA/S1P Improves Vascularization and Limits Adverse Cardiac Remodeling After Myocardial Infarction in Mice. *Human Gene Therapy*, **2019**, 30, 893-905	4.8	5
65	Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow. *Cancer Discovery*, **2019**, 9, 834-836	24.4	1
64	Engineering dendritic cell vaccines to improve cancer immunotherapy. *Nature Communications*, **2019**, 10, 5408	17.4	141
63	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. *Nature Cell Biology*, **2019**, 21, 190-202	23.4	239
62	Periostin Limits Tumor Response to VEGFA Inhibition. *Cell Reports*, **2018**, 22, 2530-2540	10.6	22

61	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. *Science Translational Medicine*, **2018**, 10,	17.5	140
60	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. *Journal of Experimental Medicine*, **2018**, 215, 859-876	16.6	104
59	EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. *Nature Methods*, **2018**, 15, 183-186	21.6	28
58	Perivascular macrophages in health and disease. *Nature Reviews Immunology*, **2018**, 18, 689-702	36.5	81
57	Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*, **2018**, 21, 425-532	13.2	285
56	Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. *Science Translational Medicine*, **2017**, 9,	17.5	292
55	CD4 T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?. *Immunity*, **2017**, 46, 773-775	31.5	33
54	The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. *Molecular Cancer Therapeutics*, **2017**, 16, 2486-2501	6.1	67
53	Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy. *Trends in Cancer*, **2017**, 3, 809-812	12.5	36
52	Microenvironmental regulation of tumour angiogenesis. *Nature Reviews Cancer*, **2017**, 17, 457-474	31.3	848
51	Primary Human and Rat β Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity. *Diabetes*, **2017**, 66, 460-473	0.9	102
50	Perivascular Macrophages Limit Permeability. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2203-2212	9.4	62
49	Suppression of microRNA activity amplifies IFN-γ induced macrophage activation and promotes anti-tumour immunity. *Nature Cell Biology*, **2016**, 18, 790-802	23.4	159
48	miR-511-3p, embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation. *Mucosal Immunology*, **2016**, 9, 960-73	9.2	25
47	Origins of Brain Tumor Macrophages. *Cancer Cell*, **2016**, 30, 832-833	24.3	14
46	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. *Cancer Research*, **2016**, 76, 3166-78	10.1	32
45	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. *Cancer Research*, **2015**, 75, 3479-91	10.1	270
44	Cancer Metastasis: Perivascular Macrophages Under Watch. *Cancer Discovery*, **2015**, 5, 906-8	24.4	11

43	A niche role for periostin and macrophages in glioblastoma. *Nature Cell Biology*, **2015**, 17, 107-9	23.4	15
42	miR-135a Inhibits Cancer Stem Cell-Driven Medulloblastoma Development by Directly Repressing Arhgef6 Expression. *Stem Cells*, **2015**, 33, 1377-89	5.8	30
41	Genetic engineering of hematopoiesis for targeted IFN- delivery inhibits breast cancer progression. *Science Translational Medicine*, **2014**, 6, 217ra3	17.5	71
40	Cancer: Metastasis risk after anti-macrophage therapy. *Nature*, **2014**, 515, 46-7	50.4	21
39	Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. *Cell Reports*, **2014**, 8, 1432-46	10.6	412
38	Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. *Cell Reports*, **2014**, 8, 696-706	10.6	170
37	Assessing metastasis risk after pre-operative anti-angiogenic therapy. *EMBO Molecular Medicine*, **2014**, 6, 1515-7	12	
36	A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. *Cancer Cell*, **2013**, 24, 559-61	24.3	29
35	Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. *Experimental Cell Research*, **2013**, 319, 1626-34	4.2	71
34	Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell*, **2013**, 23, 277-86	24.3	724
33	PHD2 regulates arteriogenic macrophages through TIE2 signalling. *EMBO Molecular Medicine*, **2013**, 5, 843-57	12	35
32	TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. *EMBO Molecular Medicine*, **2013**, 5, 858-69	12	66
31	The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. *Molecular Oncology*, **2012**, 6, 111-27	7.9	118
30	Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages. *Journal of Pathology*, **2012**, 227, 4-7	9.4	18
29	Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies. *Cancer Discovery*, **2012**, 2, 395-7	24.4	8
28	Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. *Brain*, **2012**, 135, 447-60	11.2	165
27	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. *Nature*, **2011**, 479, 122-6	50.4	237
26	Proangiogenic Tie2(+) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. *American Journal of Pathology*, **2011**, 179, 2651-9	5.8	81

25	Macrophage regulation of tumor angiogenesis: implications for cancer therapy. *Molecular Aspects of Medicine*, **2011**, 32, 123-45	16.7	127
24	The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. *International Journal of Developmental Biology*, **2011**, 55, 495-503	1.9	154
23	TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. *Journal of Clinical Investigation*, **2011**, 121, 1969-73	15.9	185
22	HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. *Cancer Cell*, **2011**, 19, 31-44	24.3	528
21	Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. *Cancer Cell*, **2011**, 19, 512-26	24.3	464
20	Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 741-9	9.4	93
19	Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. *Journal of Immunology*, **2011**, 187, 2181-92	5.3	108
18	Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. *Clinical Cancer Research*, **2011**, 17, 5226-32	12.9	74
17	Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. *Journal of Immunology*, **2011**, 186, 4183-90	5.3	150
16	Antagonizing metastasis. *Nature Biotechnology*, **2010**, 28, 331-2	44.5	4
15	A double agent in cancer: deciphering macrophage roles in human tumors. *Nature Medicine*, **2010**, 16, 861-2	50.5	23
14	Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. *Cancer Research*, **2010**, 70, 5270-80	10.1	238
13	Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. *Cancer Research*, **2010**, 70, 7500-13	10.1	157
12	Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. *American Journal of Pathology*, **2010**, 176, 1564-76	5.8	123
11	FcRgamma activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell*, **2010**, 17, 121-34	24.3	430
10	Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. *Cancer Cell*, **2008**, 14, 299-311	24.3	215
9	HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. *Leukemia*, **2007**, 21, 2067-70	10.7	19
8	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. *Blood*, **2007**, 109, 5276-85	2.2	398

7	Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. *Cancer Research*, **2007**, 67, 8429-32	10.1	221
6	Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. *Blood*, **2005**, 105, 2307-15	2.2	144
5	Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell*, **2005**, 8, 211-26	24.3	1076
4	Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. *Journal of Clinical Investigation*, **2004**, 113, 1118-1129	15.9	226
3	Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. *Nature Medicine*, **2003**, 9, 789-95	50.5	496
2	In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. *Human Gene Therapy*, **2003**, 14, 1193-206	4.8	105
1	Transduction of a gene expression cassette using advanced generation lentiviral vectors. *Methods in Enzymology*, **2002**, 346, 514-29	1.7	64